BioAlliance suspends liver cancer trial

Following advice from the Drug Safety Monitoring Board, BioAlliance has suspended a Phase II/III trial of doxorubicin Transdrug for liver cancer. The drug did show clinical activity; however, it also resulted in "frequent and more severe pulmonary adverse events than expected," according to BioAlliance. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.